تجاوز إلى المحتوى الرئيسي
drug protocol number
CKJX839A12
drug sponsor
Novartis
drug study
Inclisiran
drug trial site
Saud Al-Babtain Cardiac Center (Dammam) , King Salman Armed Forces Hospital(Tabuk) , King Fahd Armed Forces Hospital (Jeddah) , Dr. Sulaiman Al-Habib Medical Group Rayan (Riyadh),King Faisal Specialist Hospital and Research Center (Jeddah), Dr. Sulaiman Al-Habib Medical Group Olaya (Riyadh), International Medical Center (Jeddah)
drug status
Ongoing
drug phase